We provide model-informed, data-driven solutions to support biotech companies across all stages of drug development - from first-in-human studies to portfolio strategy and value optimization.
​
Our integrated approach combines pharmacometrics, model-based meta-analysis (MBMA), machine learning, and real-world evidence to reduce development risk, accelerate decision-making, and maximize asset value.​

Asset Valuation Maximization​

By providing authoritative third-party quantitative pharmacology evaluation reports, We are dedicated to helping our partners prove the Best-in-Class (BIC) potential of their assets to investors during roadshows and due diligence, significantly increasing asset valuation and financing success rates.

Globalization & MRCT Optimization

we specialize in Ethnicity Sensitivity Analysis and MRCT (Multi-Regional Clinical Trial) strategy optimization. Through precise modeling and simulation, we support the seamless dosage bridging between Phase I data and Phase II/III trials, helping products enter core global regulatory markets at the lowest cost and maximum speed.

Drug development is high-risk, time-consuming, and resource-intensive - especially for biotech companies operating with limited data and capital.
We exist to reduce that risk.
By transforming data into actionable insights, we help our clients:

• Move faster with greater confidence

• Avoid costly late-stage failures

• Maximize the value of their assets

Data to Decision -
​Faster, Smarter, with Confidence​

Our Value

Quantitative Pharmacology &
​Model-Informed Drug Development​

Our Services

​Model-Based Meta-Analysis
​​(MBMA&NMA)

Integrate data across clinical studies to generate quantitative insights for strategic decision-making.
​
Key Applications

• Competitive landscape assessment

• Go / No-Go decision support

• Probability of success (PoS) estimation

• Cross-indication extrapolation

• Indirect treatment comparisons without head-to-head trials

• Integrated efficacy and safety benchmarking

Apply advanced pharmacometric modeling to support critical development decisions and optimize clinical strategy.
​
​Key Applications

• PK/PD and population PK (PopPK) modeling

• Exposure–response analysis and dose optimization

• Translational modeling from preclinical to clinical

• Integrated efficacy–safety modeling

• Bayesian analysis and decision modeling

• Bridging across populations and study designs​

Machine Learning & AI-Enhanced
​Quantitative Modeling​

Apply advanced pharmacometric modeling to support critical development decisions and optimize clinical strategy.
​
​Key Applications

• PK/PD and population PK (PopPK) modeling

• Exposure–response analysis and dose optimization

• Translational modeling from preclinical to clinical

• Integrated efficacy–safety modeling

• Bayesian analysis and decision modeling

• Bridging across populations and study designs​

Real-World Evidence &
​Advanced Data Science​

Leverage real-world and external data to complement clinical evidence and support value-driven decisions.
​
Key Applications

• External validation of efficacy and safety using real-world data

• Drug value assessment for pricing and market access

• Health economics and outcomes research (HEOR)